---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-003291"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:39:11.699414+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Beam gets FDA clearance for first base editing IND (BEAM-101); Q3 net loss $28.1M, cash $933.4M

## Summary
- FDA cleared IND for BEAM-101 (sickle cell disease); first open IND for base editing.
- Beam initiated IND-enabling studies for BEAM-102 (Makassar base editing for sickle cell).
- Q3 net loss $28.1M ($0.42/share); R&D $54.6M, G&A $15.8M.
- Cash, equivalents & securities $933.4M as of Sep 30, 2021, up from $299.7M at Dec 31, 2020.
- Non-exclusive license to Sana for Cas12b for $50M upfront; potential milestones/royalties.

## SEC filing metadata
- accession: 0000950170-21-003291
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017021003291/0000950170-21-003291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017021003291/beam-20211105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-003291
- JSON: https://secwatch.observer/filing/0000950170-21-003291.json
- Plain text: https://secwatch.observer/filing/0000950170-21-003291.txt

## Key facts
- Executive change
  John Maraganore was elected as Director at Beam Therapeutics Inc..
  - Action: elected
  - Role: Director
  source text: On November 5, 2021, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from six to seven members and elected John Maraganore, Ph.D., as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017021003291/0000950170-21-003291-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.